Tumor suppressor miR‑613 induces cisplatin sensitivity in non‑small cell lung cancer cells by targeting GJA1

Luo,Jianhua; Jin,Yan; Li,Mengyuan; Dong,Liyang

doi:10.3892/mmr.2021.12024

Tumor suppressor miR‑613 induces cisplatin sensitivity in non‑small cell lung cancer cells by targeting GJA1

Authors:
- Jianhua Luo
- Yan Jin
- Mengyuan Li
- Liyang Dong
View Affiliations

Affiliations: Department of Respiratory Medicine, Taizhou Municipal Hospital, Taizhou, Zhejiang 318000, P.R. China, Department of Invasive Technology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: March 18, 2021 https://doi.org/10.3892/mmr.2021.12024
Article Number: 385
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been reported that microRNAs (miRs) contribute to several biological functions and are associated with drug resistance in various types of cancer. However, to the best of our knowledge, whether miR‑613 can affect cisplatin (CDDP) sensitivity in non‑small cell lung cancer (NSCLC) remains unknown. Reverse transcription‑quantitative PCR was performed to detect the expression levels of miR‑613 and gap junction α‑1 protein (GJA1) in patients with NSCLC. Cell Counting Kit‑8, colony formation and Transwell assays were employed to exam the effects of miR‑613 and GJA1 on cell functions. Cell apoptosis was analyzed using flow cytometry. An in vivo experiment was conducted to determine the influence of miR‑613 on tumor formation. In the present study, miR‑613 was revealed to be significantly downregulated in lung cancer tissues compared with in adjacent normal tissues, and low miR‑613 expression indicated a poor prognosis. Furthermore, cell proliferation, colony formation and migration of lung cancer cells were inhibited by overexpression of miR‑613. In vivo experiments also demonstrated that miR‑613 could inhibit tumor growth. Moreover, miR‑613 could enhance the negative effects of CDDP on cell proliferation, apoptosis and migration. GJA1 was revealed to be a target gene of miR‑613 and was upregulated in human lung cancer tissues. Rescue experiments demonstrated that miR‑613 increased the chemosensitivity of lung cancer cells by targeting GJA1. Collectively, the results suggested a tumor suppressor role of miR‑613 in NSCLC and indicated that miR‑613 could strengthen CDDP sensitivity in NSCLC cells by targeting GJA1, which may provide a novel therapeutic target for NSCLC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Nasim F, Sabath BF and Eapen GA: Lung cancer. Med Clin North Am. 103:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
3	Rodriguez-Canales J, Parra-Cuentas E and Wistuba II: Diagnosis and molecular classification of lung cancer. Cancer Treat Res. 170:25–46. 2016. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Zeng H, Zhang S and He J: Annual report on status of cancer in China, 2011. Chin J Cancer Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zou XN, Lin DM, Wan X, Chao A, Feng QF, Dai Z, Yang GH and Lv N: Histological subtypes of lung cancer in Chinese males from 2000 to 2012. Biomed Environ Sci. 27:3–9. 2014.PubMed/NCBI
6	Wang S, Liu F, Zhu J, Chen P, Liu H, Liu Q and Han J: DNA repair genes ERCC1 and BRCA1 expression in non-small cell lung cancer chemotherapy drug resistance. Med Sci Monit. 22:1999–2005. 2016. View Article : Google Scholar : PubMed/NCBI
7	Umihanic S, Umihanic S, Jamakosmanovic S, Brkic S, Osmic M, Dedic S and Ramic N: Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV. Med Arch. 68:83–85. 2014. View Article : Google Scholar : PubMed/NCBI
8	Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L and Nelson PS: Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 18:1359–1368. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
10	Johnson DH, Schiller JH and Bunn PA Jr: Recent clinical advances in lung cancer management. J Clin Oncol. 32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
11	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kelman AD and Peresie HJ: Mode of DNA binding of cis-platinum(II) antitumor drugs: A base sequence-dependent mechanism is proposed. Cancer Treat Rep. 63:1445–1452. 1979.PubMed/NCBI
13	Giaccone G: Clinical perspectives on platinum resistance. Drugs. 59 (Suppl 4):S9–S17, S37-S38. 2000. View Article : Google Scholar
14	Momekov G, Ferdinandov D, Bakalova A, Zaharieva M, Konstantinov S and Karaivanova M: In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands. Arch Toxicol. 80:555–560. 2006. View Article : Google Scholar : PubMed/NCBI
15	Eljack ND, Ma HY, Drucker J, Shen C, Hambley TW, New EJ, Friedrich T and Clarke RJ: Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics. 6:2126–2133. 2014. View Article : Google Scholar : PubMed/NCBI
16	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
17	Tutar L, Özgür A and Tutar Y: Involvement of miRNAs and pseudogenes in cancer. Methods Mol Biol. 1699:45–66. 2018. View Article : Google Scholar : PubMed/NCBI
18	Tan S, Sun D, Pu W, Gou Q, Guo C, Gong Y, Li J, Wei YQ, Liu L, Zhao Y and Peng Y: Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer. Mol Cancer. 17:1382018. View Article : Google Scholar : PubMed/NCBI
19	Wu KL, Tsai YM, Lien CT, Kuo PL and Hung AJ: The roles of MicroRNA in lung cancer. Int J Mol Sci. 20:16112019. View Article : Google Scholar
20	Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA, Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem Biophys Res Commun. 435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
21	Allen KE and Weiss GJ: Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ma Y, Li X, Cheng S, Wei W and Li Y: MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Mol Med Rep. 11:625–632. 2015. View Article : Google Scholar : PubMed/NCBI
23	Jiang X, Wu J, Zhang Y, Wang S, Yu X, Li R and Huang X: MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. Gene. 659:168–174. 2018. View Article : Google Scholar : PubMed/NCBI
24	Su X, Gao C, Feng X and Jiang M: miR-613 suppresses migration and invasion in esophageal squamous cell carcinoma via the targeting of G6PD. Exp Ther Med. 19:3081–3089. 2020.PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Li C, Zhao W, Pan X, Li X, Yan F, Liu S, Feng J and Lu J: LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1. Oncogene. 39:6157–6171. 2020. View Article : Google Scholar : PubMed/NCBI
27	Mengoli MC, Longo FR, Fraggetta F, Cavazza A, Dubini A, Alì G, Guddo F, Gilioli E, Bogina G, Nannini N, et al: The 2015 world health organization classification of lung tumors: New entities since the 2004 classification. Pathologica. 110:39–67. 2018.PubMed/NCBI
28	Vasconcellos VF, Marta GN, da Silva EM, Gois AF, de Castria TB and Riera R: Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 1:CD0092562020.PubMed/NCBI
29	Rotolo F, Dunant A, Le Chevalier T, Pignon JP and Arriagada R; IALT Collaborative Group, : Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: New insights into the effect on failure type via a multistate approach. Ann Oncol. 25:2162–2166. 2014. View Article : Google Scholar : PubMed/NCBI
30	Hu J, Xu C, Cheng B, Jin L, Li J, Gong Y, Lin W, Pan Z and Pan C: Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy. Tumour Biol. 37:331–339. 2016. View Article : Google Scholar : PubMed/NCBI
31	Wang L, Shi ZM, Jiang CF, Liu X, Chen QD, Qian X, Li DM, Ge X, Wang XF, Liu LZ, et al: MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget. 5:5416–5427. 2014. View Article : Google Scholar : PubMed/NCBI
32	Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu K and Fan D: MicroRNA-21: A therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets. 17:1073–1080. 2013. View Article : Google Scholar : PubMed/NCBI
33	Zhao Z, Lv B, Zhang L, Zhao N and Lv Y: miR-202 functions as a tumor suppressor in non-small cell lung cancer by targeting STAT3. Mol Med Rep. 16:2281–2289. 2017. View Article : Google Scholar : PubMed/NCBI
34	Shi ZM, Wang L, Shen H, Jiang CF, Ge X, Li DM, Wen YY, Sun HR, Pan MH, Li W, et al: Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling. Oncogene. 36:2577–2588. 2017. View Article : Google Scholar : PubMed/NCBI
35	Dong Z, Zhong Z, Yang L, Wang S and Gong Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
36	Ning FL, Wang F, Li ML, Yu ZS, Hao YZ and Chen SS: MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagn Pathol. 9:1432014. View Article : Google Scholar : PubMed/NCBI
37	Li Y, Li L, Guan Y, Liu X, Meng Q and Guo Q: MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Biochem Biophys Res Commun. 440:604–610. 2013. View Article : Google Scholar : PubMed/NCBI
38	Feng B, Wang R, Song HZ and Chen LB: MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer. 118:3365–3376. 2012. View Article : Google Scholar : PubMed/NCBI
39	Li B, Liu D, Yang P, Li HY and Wang D: miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway. Gene. 707:78–85. 2019. View Article : Google Scholar : PubMed/NCBI
40	Goodenough DA and Paul DL: Beyond the gap: Functions of unpaired connexon channels. Nat Rev Mol Cell Biol. 4:285–294. 2003. View Article : Google Scholar : PubMed/NCBI
41	James CC, Zeitz MJ, Calhoun PJ, Lamouille S and Smyth JW: Altered translation initiation of Gja1 limits gap junction formation during epithelial-mesenchymal transition. Mol Biol Cell. 29:797–808. 2018. View Article : Google Scholar : PubMed/NCBI